Format

Send to

Choose Destination
Clin Cancer Res. 2015 Mar 1;21(5):1207-14. doi: 10.1158/1078-0432.CCR-14-2011. Epub 2014 Dec 29.

A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.

Author information

1
Department of Genetics, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. Department of Research, Vestre Viken, Drammen, Norway.
2
Oncology Experimental Therapeutics Unit, IRCCS Clinical and Research Institute Humanitas, Rozzano-Milan, Italy.
3
Department of Oncology, Division of Surgery and Cancer Medicine, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. K.G. Jebsen Centre for Breast Cancer, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
4
Division of Molecular Biology of Breast Cancer, University Women's Clinic, Heidelberg, Germany. Molecular Epidemiology, German Cancer Research Center, Heidelberg, Germany.
5
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
6
Department of Genetics, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. K.G. Jebsen Centre for Breast Cancer, Institute for Clinical Medicine, University of Oslo, Oslo, Norway. libero.santarpia@humanitasresearch.it a.l.borresen-dale@medisin.uio.no.
7
Oncology Experimental Therapeutics Unit, IRCCS Clinical and Research Institute Humanitas, Rozzano-Milan, Italy. libero.santarpia@humanitasresearch.it a.l.borresen-dale@medisin.uio.no.

Abstract

PURPOSE:

Triple-negative breast cancers (TNBC) are associated with high risk of early tumor recurrence and poor outcome. Common prognostic biomarkers give very restricted predictive information of tumor recurrences in TNBC. Human serum contains stably expressed microRNAs (miRNAs), which have been discovered to predict prognosis in patients with cancer. The purpose of this study was to identify circulating biomarkers able to predict clinical outcome in TNBC.

EXPERIMENTAL DESIGN:

We performed genome-wide serum miRNA expression and real-time PCR analyses to investigate the ability of miRNAs in predicting tumor relapse in serum samples from 60 primary TNBC. Patients were divided into training and testing cohorts.

RESULTS:

By Cox regression analysis, we identified a four-miRNA signature (miR-18b, miR-103, miR-107, and miR-652) that predicted tumor relapse and overall survival. This miRNA signature was further validated in an independent cohort of 70 TNBC. A high-risk signature score was developed and significantly associated with tumor recurrence and reduced survival. Multivariate Cox regression models indicated that the risk score based on the four-miRNA signature was an independent prognostic classifier of patients with TNBC.

CONCLUSIONS:

This signature may serve as a minimally invasive predictor of tumor relapse and overall survival for patients with TNBC. This prediction model may ultimately lead to better treatment options for patients with TNBC.

PMID:
25547678
DOI:
10.1158/1078-0432.CCR-14-2011
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire Icon for Norwegian BIBSYS system
Loading ...
Support Center